Cipla Share Price
1385.00-9.70 (-0.70%)
-12.25% past 1 Year
News
Morgan Stanley maintains underweight on Cipla, notes Qilu biosimilar tie-up
Equity
CIPLA
Cipla unit Invagen inks exclusive Keytruda biosimilar deal with Qilu
Equity
CIPLA
Cipla signs exclusive licensing deal for HER2 bispecific ADC in emerging markets
Equity
CIPLA
Cipla unit Invagen Pharmaceuticals inspection classified as VAI by USFDA
Equity
CIPLA
Cipla completes restructuring giving Aspergen Limited full control of Aspergen Inc
Equity
CIPLA
Cipla receives USFDA observations at Pithampur facility, Citi keeps Buy rating
Equity
CIPLA
Cipla receives USFDA Form 483 with seven observations for Pithampur unit
Equity
CIPLA
Cipla receives USFDA Form 483 with seven observations at Pithampur plant
Equity
CIPLA
USFDA inspects Cipla’s Indore Unit IV, key revenue contributing plant
Equity
CIPLA
Block trade in Cipla shares on BSE worth Rs 58.32 crores at Rs 1458
Equity
CIPLA
Cipla receives USFDA approval confirmation for Invagen New York facility
Equity
CIPLA
Cipla receives USFDA nod for generic Advair Diskus asthma, COPD inhaler
Equity
CIPLA
Nomura retains Buy on Cipla, sees margin recovery driven by US launches
Equity
CIPLA
Cipla gains as Citi reiterates Buy with Rs 1,700 target on earnings outlook
Equity
CIPLA
Cipla gains support as JPM maintains overweight, targets Rs 1,600 on margin outlook
Equity
CIPLA
Cipla posts record Q1 FY27 revenue, maintains EBITDA margin guidance
Equity
CIPLA
Cipla targets stronger North America growth with new launches, Ventolin ramp-up
Equity
CIPLA
Cipla US pipeline to see four key launches including generic Advair
Equity
CIPLA
Cipla reiterates FY27 EBITDA margin guidance range in latest concall update
Equity
CIPLA
Cipla plans new product launches and distribution network expansion
Equity
CIPLA